Sientra’s (SIEN) Buy Rating Reiterated at Maxim Group

Sientra (NASDAQ:SIEN – Get Rating)‘s stock had its “buy” rating restated by analysts at Maxim Group in a research report issued to clients and investors on Friday, TipRanks reports. They currently have a $5.00 price objective on the medical instruments supplier’s stock. Maxim Group’s price target points to a potential upside of 320.17% from the stock’s previous close.

Other equities analysts have also issued research reports about the stock. Canaccord Genuity Group decreased their target price on shares of Sientra from $10.00 to $8.00 and set a “buy” rating for the company in a research report on Tuesday, March 29th. Zacks Investment Research downgraded shares of Sientra from a “hold” rating to a “sell” rating in a report on Tuesday, March 29th. UBS Group cut their price target on shares of Sientra from $10.00 to $8.00 and set a “buy” rating for the company in a report on Tuesday, March 29th. Canaccord Genuity Group cut their price target on shares of Sientra from $8.00 to $5.00 in a report on Friday. Finally, StockNews.com downgraded shares of Sientra from a “hold” rating to a “sell” rating in a report on Tuesday. Two analysts have rated the stock with a sell rating and eight have issued a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $7.20.

SIEN traded down $0.10 on Friday, reaching $1.19. The company had a trading volume of 1,286,289 shares, compared to its average volume of 901,432. The company has a fifty day moving average of $1.94 and a 200-day moving average of $3.10. The company has a market capitalization of $74.21 million, a P/E ratio of -1.20 and a beta of 2.11. The company has a current ratio of 1.76, a quick ratio of 1.10 and a debt-to-equity ratio of 1.53. Sientra has a one year low of $1.18 and a one year high of $9.14.

Sientra (NASDAQ:SIEN – Get Rating) last announced its earnings results on Wednesday, March 23rd. The medical instruments supplier reported ($0.27) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.08). The company had revenue of $22.65 million during the quarter, compared to the consensus estimate of $22.50 million. Sientra had a negative net margin of 112.89% and a negative return on equity of 865.36%. During the same quarter in the prior year, the company earned ($0.38) EPS. Research analysts predict that Sientra will post -0.88 EPS for the current year.

A number of hedge funds have recently bought and sold shares of the business. BlackRock Inc. lifted its stake in Sientra by 2.0% during the first quarter. BlackRock Inc. now owns 3,768,538 shares of the medical instruments supplier’s stock valued at $8,366,000 after buying an additional 74,896 shares in the last quarter. Morgan Stanley increased its holdings in shares of Sientra by 11.2% in the 3rd quarter. Morgan Stanley now owns 3,117,077 shares of the medical instruments supplier’s stock valued at $17,861,000 after purchasing an additional 314,815 shares during the period. Vanguard Group Inc. increased its holdings in shares of Sientra by 13.3% in the 1st quarter. Vanguard Group Inc. now owns 3,106,395 shares of the medical instruments supplier’s stock valued at $6,896,000 after purchasing an additional 364,180 shares during the period. Senvest Management LLC increased its holdings in shares of Sientra by 8.1% in the 4th quarter. Senvest Management LLC now owns 2,861,039 shares of the medical instruments supplier’s stock valued at $10,500,000 after purchasing an additional 215,000 shares during the period. Finally, Schroder Investment Management Group increased its holdings in shares of Sientra by 3.0% in the 4th quarter. Schroder Investment Management Group now owns 2,837,877 shares of the medical instruments supplier’s stock valued at $10,415,000 after purchasing an additional 81,659 shares during the period. 82.42% of the stock is owned by institutional investors.

Sientra Company Profile (Get Rating)

Sientra, Inc, a medical aesthetics company, develops and sells medical aesthetics products in the United States and internationally. It offers silicone gel breast implants for use in breast augmentation and breast reconstruction procedures; breast tissue expanders; and scar management products under the Sientra Round, Sientra Teardrop, AlloX2, Dermaspan, Softspan, and BIOCORNEUM brand names.

Further Reading